Literature DB >> 15968073

Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression.

D O Chaffin1, L M Mentele, C E Rubens.   

Abstract

Several bacterial pathogens have evolved the means to escape immune detection by mimicking host cell surface carbohydrates that are crucial for self/non-self recognition. Sialic acid, a terminal residue on these carbohydrates, inhibits activation of the alternate pathway of complement by recruiting the immune modulating molecule factors H, I, and iC3b. Sialylation of capsular polysaccharide (CPS) is important for virulence of group B streptococci (GBS), a significant human pathogen. We previously reported that cpsK, a gene within the cps locus of type III GBS, could complement a sialyltransferase deficient lst mutant of Haemophilus ducreyi, implicating its role in sialylation of the GBS capsule. To explore the function of cpsK in GBS capsule production, we created a mutant in cpsK. Immunoblot analysis and enzyme-linked immunosorbent assay using anti-type III CPS antisera demonstrated that the mutant CPS did not contain sialic acid. This was confirmed by high-performance liquid chromatography after mild acid hydrolysis of the CPS. Although increased CPS chain length was seen for this strain, CPS production was <20% of the parental isolate. An episomal cpsK copy restored synthesis of sialo-CPS to wild-type levels. These data support our hypothesis that cpsK encodes the GBS CPS sialyltransferase and provide further evidence that lack of CPS oligosaccharide sialylation reduces the amount of CPS expressed on the cell surface. These observations also imply that one or more of the components involved in synthesis or transport of oligosaccharide repeating units requires a sialo-oligosaccharide for complete activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968073      PMCID: PMC1151781          DOI: 10.1128/JB.187.13.4615-4626.2005

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  47 in total

1.  Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci.

Authors:  M J Cieslewicz; D L Kasper; Y Wang; M R Wessels
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

2.  Production of capsular polysaccharide of Streptococcus pneumoniae type 14 and its purification by affinity chromatography.

Authors:  N Suárez; L F Fraguas; E Texeira; H Massaldi; F Batista-Viera; F Ferreira
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

3.  Quantitative determination of pneumococcal capsular polysaccharide serotype 14 using a modification of phenol-sulfuric acid method.

Authors:  Gabriela Cuesta; Norma Suarez; Maria I Bessio; Fernando Ferreira; Hugo Massaldi
Journal:  J Microbiol Methods       Date:  2003-01       Impact factor: 2.363

4.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.

Authors:  S J Schrag; S Zywicki; M M Farley; A L Reingold; L H Harrison; L B Lefkowitz; J L Hadler; R Danila; P R Cieslak; A Schuchat
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

5.  Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.

Authors:  M S Edwards; D L Kasper; H J Jennings; C J Baker; A Nicholson-Weller
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

6.  The serotype of type Ia and III group B streptococci is determined by the polymerase gene within the polycistronic capsule operon.

Authors:  D O Chaffin; S B Beres; H H Yim; C E Rubens
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

7.  Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.

Authors:  Hilde-Kari Guttormsen; Carol J Baker; Moon H Nahm; Lawrence C Paoletti; Susu M Zughaier; Morven S Edwards; Dennis L Kasper
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

8.  CpsB is a modulator of capsule-associated tyrosine kinase activity in Streptococcus pneumoniae.

Authors:  M H Bender; J Yother
Journal:  J Biol Chem       Date:  2001-10-17       Impact factor: 5.157

9.  CpsK of Streptococcus agalactiae exhibits alpha2,3-sialyltransferase activity in Haemophilus ducreyi.

Authors:  Donald O Chaffin; Katherine McKinnon; Craig E Rubens
Journal:  Mol Microbiol       Date:  2002-07       Impact factor: 3.501

10.  Group B, type III streptococcal cell wall: composition and structural aspects revealed through endo-N-acetylmuramidase-catalyzed hydrolysis.

Authors:  B J De Cueninck; G D Shockman; R M Swenson
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

View more
  30 in total

1.  L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci.

Authors:  Mioko Fujieda; Youko Aoyagi; Kousaku Matsubara; Yasuhito Takeuchi; Wakae Fujimaki; Misao Matsushita; John F Bohnsack; Shinji Takahashi
Journal:  Infect Immun       Date:  2012-03-26       Impact factor: 3.441

2.  Identification of Group B Streptococcus Capsule Type by Use of a Dual Phenotypic/Genotypic Assay.

Authors:  Areej Alhhazmi; Armaan Pandey; Gregory J Tyrrell
Journal:  J Clin Microbiol       Date:  2017-06-14       Impact factor: 5.948

3.  Group B streptococcus exploits vaginal epithelial exfoliation for ascending infection.

Authors:  Jay Vornhagen; Blair Armistead; Verónica Santana-Ufret; Claire Gendrin; Sean Merillat; Michelle Coleman; Phoenicia Quach; Erica Boldenow; Varchita Alishetti; Christina Leonhard-Melief; Lisa Y Ngo; Christopher Whidbey; Kelly S Doran; Chad Curtis; Kristina M Adams Waldorf; Elizabeth Nance; Lakshmi Rajagopal
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

4.  Sialic acid catabolism confers a competitive advantage to pathogenic vibrio cholerae in the mouse intestine.

Authors:  Salvador Almagro-Moreno; E Fidelma Boyd
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

5.  Crystal structure of Bacillus anthracis virulence regulator AtxA and effects of phosphorylated histidines on multimerization and activity.

Authors:  Troy G Hammerstrom; Lori B Horton; Michelle C Swick; Andrzej Joachimiak; Jerzy Osipiuk; Theresa M Koehler
Journal:  Mol Microbiol       Date:  2014-12-30       Impact factor: 3.501

6.  The sensor histidine kinase RgfC affects group B streptococcal virulence factor expression independent of its response regulator RgfA.

Authors:  Claire Gendrin; Annalisa Lembo; Christopher Whidbey; Kellie Burnside; Jessica Berry; Lisa Ngo; Anirban Banerjee; Liang Xue; Justine Arrington; Kelly S Doran; W Andy Tao; Lakshmi Rajagopal
Journal:  Infect Immun       Date:  2015-01-05       Impact factor: 3.441

7.  Bacillus anthracis virulence regulator AtxA: oligomeric state, function and CO(2) -signalling.

Authors:  Troy G Hammerstrom; Jung Hyeob Roh; Edward P Nikonowicz; Theresa M Koehler
Journal:  Mol Microbiol       Date:  2011-10-10       Impact factor: 3.501

8.  Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes.

Authors:  Aaron F Carlin; Amanda L Lewis; Ajit Varki; Victor Nizet
Journal:  J Bacteriol       Date:  2006-09-22       Impact factor: 3.490

9.  Modulation of the Bacillus anthracis secretome by the immune inhibitor A1 protease.

Authors:  Kathryn J Pflughoeft; Michelle C Swick; David A Engler; Hye-Jeong Yeo; Theresa M Koehler
Journal:  J Bacteriol       Date:  2013-11-08       Impact factor: 3.490

10.  Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathways.

Authors:  Cynthia Calzas; Guillaume Goyette-Desjardins; Paul Lemire; Fleur Gagnon; Claude Lachance; Marie-Rose Van Calsteren; Mariela Segura
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.